Cargando…
Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey
BACKGROUND: Antimalarial agents (AMs), mainly hydroxychloroquine (HCQ) and chloroquine, are the cornerstone of treatment of cutaneous and systemic lupus erythematosus. However, many aspects of AM prescription remain empirical. The aim of this study was to assess the modalities of AM prescription amo...
Autores principales: | Petitdemange, Arthur, Felten, Renaud, Sibilia, Jean, Martin, Thierry, Arnaud, Laurent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138289/ https://www.ncbi.nlm.nih.gov/pubmed/34046091 http://dx.doi.org/10.1177/1759720X211002595 |
Ejemplares similares
-
Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis
por: Petitdemange, Arthur, et al.
Publicado: (2020) -
Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage
por: Blaess, Julien, et al.
Publicado: (2020) -
Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge
por: Dima, Alina, et al.
Publicado: (2022) -
Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study
por: Felten, Renaud, et al.
Publicado: (2021) -
Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date
por: Felten, Renaud, et al.
Publicado: (2019)